If you have been reading about lyophilised powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-24. Numbers and descriptions here follow the published literature rather than marketing material.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilised cake or powder |
| Solubility class | Freely soluble in water | Aqueous buffers also used |
| Typical storage temperature | About -20 degrees Celsius | Dry, sealed and protected from light |
| Typical analytical method | Reversed-phase HPLC or LC-MS/MS | Used for purity, identity and quantification |
| Common synonyms | Thymosin beta-4 fragment | Also listed under fragment-based descriptions |
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
However, the Western Allies (the US, UK, and France) never formally acknowledged the authority of the East German government to govern East Berlin; the official Allied protocol recognised only the authority of the Soviet Union in East Berlin in accordance with the occupation status of Berlin as a whole.
Resistin is a cysteine-rich, secreted peptide hormone characterized by a unique multimeric structure. Each resistin monomer consists of a C-terminal, disulfide-rich beta-sandwich "head" domain and an N-terminal alpha-helical "tail" segment. The head domain adopts a six-stranded jelly-roll topology, forming two three-stranded antiparallel beta-sheets, while the tail segments associate to create three-stranded coiled coils. These monomers assemble into trimers, and further interchain disulfide linkages mediate the formation of tail-to-tail hexamers, resulting in a multimeric assembly stabilized by disulfide bonds. In circulation, resistin exists in multiple assembly states, including high-molecular-mass hexamers and lower-molecular-mass trimers, with the oligomeric form in humans showing greater proinflammatory activity. This structural organization is highly conserved within the resistin-like molecule family of peptide hormones.
=== Enlarged prostate === Flutamide has been studied in the treatment of benign prostatic hyperplasia (BPH; enlarged prostate) in men in several clinical studies. It has been found to reduce prostate volume by about 25%, which is comparable to the reduction achieved with the 5α-reductase inhibitor finasteride. Unfortunately, it has been associated with side effects in these studies including gynecomastia and breast tenderness (in about 50% of patients), gastrointestinal disturbances such as nausea, diarrhea, and flatulence, and hepatotoxicity, although sexual function including libido and erectile potency were maintained.
Gamma irradiation is widely used due to its high penetration depth and dose uniformity, allowing for large-scale applications with high throughput. Additionally, gamma irradiation is significantly less expensive than using an X-ray source. In most designs, the radioisotope, contained in stainless steel pencils, is stored in a water-filled storage pool which absorbs the radiation energy when not in use. For treatment, the source is lifted out of the storage tank, and product contained in totes is passed around the pencils to achieve required processing. Treatment costs vary as a function of dose and facility usage. A pallet or tote is typically exposed for several minutes to hours depending on dose. Low-dose applications such as disinfestation of fruit range between US$0.01/lb and US$0.08/lb while higher-dose applications can cost as much as US$0.20/lb.
Sources: en.wikipedia.org
=== Angiogenesis for cardiovascular disease === Angiogenesis represents an excellent therapeutic target for the treatment of cardiovascular disease. It is a potent, physiological process that underlies the natural manner in which our bodies respond to a diminution of blood supply to vital organs, namely neoangiogenesis: the production of new collateral vessels to overcome the ischemic insult. A large number of preclinical studies have been performed with protein-, gene- and cell-based therapies in animal models of cardiac ischemia, as well as models of peripheral artery disease. Reproducible and credible successes in these early animal studies led to high enthusiasm that this new therapeutic approach could be rapidly translated to a clinical benefit for millions of patients in the Western world with these disorders. A decade of clinical testing both gene- and protein-based therapies designed to stimulate angiogenesis in underperfused tissues and organs, however, has led from one disappointment to another. Although all of these preclinical readouts, which offered great promise for the transition of angiogenesis therapy from animals to humans, were in one fashion or another, incorporated into early stage clinical trials, the FDA has, to date (2007), insisted that the primary endpoint for approval of an angiogenic agent must be an improvement in exercise performance of treated patients.
=== Anti-atherosclerotic and anti-inflammatory effects === 1-MNA exhibits anti-atherosclerotic and anti-inflammatory properties by improving the prostacyclin- and NO-dependent secretory function of the vascular endothelium, inhibiting platelet activation, reducing inflammation within atherosclerotic plaques, and lowering systemic inflammation and TNF-α levels. The anti-inflammatory effects of 1-MNA are linked to its ability to stimulate endogenous PGI2 secretion and reduce IL-4 and TNF-α levels. These effects are mediated by endothelial mechanisms rather than a direct impact on immune cell function, ensuring that the body's immune response is not weakened.
Somalia evolved into a major world supplier of uranium, with American, UAE, Italian and Brazilian mineral companies vying for extraction rights. Link Natural Resources has a stake in the central region, and Kilimanjaro Capital has a stake in the 1,161,400 acres (470,002 ha) Amsas-Coriole-Afgoi (ACA) Block, which includes uranium exploration. The Trans-National Industrial Electricity and Gas Company is an energy conglomerate based in Mogadishu. It unites five major Somali companies from the trade, finance, security and telecommunications sectors, following a 2010 joint agreement signed in Istanbul to provide electricity and gas infrastructure in Somalia. With an initial investment budget of $1 billion, the company launched a labour-intensive energy program aimed at facilitating local industrialisation initiatives. According to the Central Bank of Somalia, as the nation embarks on the path of reconstruction, the economy is expected not only to match its pre-civil war levels, but also to accelerate in growth and development due to Somalia's untapped natural resources.
Species of Epimedium are herbaceous perennials, growing from an underground rhizome. Their growth habits are somewhat variable. Some have solitary stems, others have a "tufted" habit, with multiple stems growing close together. There may be several leaves to a stem or the leaves may be solitary, produced from the base of the plant. Individual leaves are generally compound, often with three leaflets, but also with more. Leaflets usually have spiny margins. The leaves may be annual, making the plant deciduous, or longer lasting, so that the plant is evergreen. The inflorescence is an open raceme or panicle, the number of flowers varying by species. Individual flowers have parts in fours. There are four smaller outer sepals, usually greenish and shed when the flower opens. Moving inwards, they are followed by four larger petal-like inner sepals, often brightly colored. Inside the sepals are four true petals which may be small and flat, but often have a complex shape including a nectar-producing "spur" that may be longer than the sepals. There are four stamens. One of the common names for the genus, bishop's hat, arises from the shape of the flowers, particularly where the spurs are longer than the sepals.
=== Transdermal administration === Progesterone for transdermal administration is not approved by the FDA in the United States. Multiple pharmaceutical companies have pursued the development of systemic transdermal progesterone formulations, but ultimately none have successfully been developed and introduced for clinical use. Although no formulations of transdermal progesterone are approved for systemic use, a 1% topical gel formulation of progesterone for local use on the breasts is approved to treat breast pain under the brand name Progestogel in various countries. Although no formulations of transdermal progesterone are approved for systemic use, transdermal progesterone is available in the form of creams and gels from custom compounding pharmacies in some countries, and is also available over-the-counter without a prescription in the United States. Transdermal progesterone has been used by thousands of women as a component of menopausal hormone therapy in the United States and Europe. However, these products are unregulated and have not been clinically tested, often with little being known about their pharmacokinetics. In addition, the absorption of transdermal progesterone may differ significantly from formulation to formulation due to widely varying ingredients. Moreover, the systemic effectiveness of transdermal progesterone in producing therapeutic progestogenic effects, most importantly adequate endometrial protection against estrogens, is controversial.
Sources: en.wikipedia.org
Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.
Reported purity reflects the batch tested, the chromatographic method used and whether an independent laboratory performed the work. Values quoted without method detail or a traceable certificate are difficult to compare directly.
Short peptides are rapidly broken down by proteases and appear at low concentrations in urine, so the detection window is narrow. Sensitive extraction combined with tandem mass spectrometry is typically required.
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.